New drug combo targets deadly breast cancer pathway
NCT ID NCT02876302
Summary
This study is testing whether adding the drug ruxolitinib to standard chemotherapy before surgery helps control triple-negative inflammatory breast cancer, a particularly aggressive form. Researchers are enrolling 23 adults with this specific cancer type to see if blocking a particular cancer growth pathway makes treatment more effective. The study measures whether tumors shrink completely before surgery and tracks how long patients remain cancer-free after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BREAST CANCER (IBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.